Pacira BioSciences, Inc. (PCRX) stock
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Earnings
Pacira BioSciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Pacira BioSciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026after the close | $192.40M | +6.2% | $0.12 | $0.73 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 30, 2026after the close | $177.40M | +5.0% | $0.07 | $0.60 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026after the close | $196.90M | +5.1% | $0.04 | $0.57 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $179.50M | +6.5% | $0.12 | $0.70 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025after the close | $181.10M | +1.7% | -$0.11 | $0.74 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | $168.90M | +1.1% | $0.10 | $0.62 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025after the close | $187.30M | +3.4% | $0.34 | $0.91 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024after the close | $168.60M | +2.9% | -$3.11 | $0.79 | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 30, 2024after the close | $178.00M | +5.0% | $0.39 | $0.89 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024after the close | $167.10M | +4.2% | $0.19 | $0.62 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 29, 2024before the open | $181.20M | +5.3% | $0.50 | $0.89 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023before the open | $163.90M | -2.1% | $0.23 | $0.72 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 2, 2023before the open | $169.50M | +0.1% | $0.51 | $0.78 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 3, 2023before the open | $160.30M | +1.5% | -$0.43 | $0.53 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023before the open | $172.00M | +8.0% | -$0.22 | $0.80 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | $167.50M | +31.2% | -$0.02 | $0.64 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022before the open | $169.40M | – | $0.40 | $0.51 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022before the open | $158.00M | – | $0.15 | $0.64 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022before the open | $159.20M | – | -$0.12 | $0.97 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021before the open | $127.70M | – | $0.39 | $0.72 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 13, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 7, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 10, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 7, 2020before the open | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 6, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Pacira BioSciences's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total revenue | FY2026 | $735.00M – $760.00M | $745.00M – $770.00M | Raised | Aug 4, 2026 |
| Total revenue | FY2026 | $745.00M – $770.00M | – | New | Feb 26, 2026 |
| Gross marginGAAP | FY2026 | 76% – 78% | 76% – 78% | Reaffirmed | Aug 4, 2026 |
| Gross marginGAAP | FY2026 | 76% – 78% | – | New | Feb 26, 2026 |
| Non-GAAP gross marginnon-GAAP | FY2026 | 77% – 79% | 77% – 79% | Reaffirmed | Aug 4, 2026 |
| Non-GAAP gross marginnon-GAAP | FY2026 | 77% – 79% | – | New | Feb 26, 2026 |
| EXPAREL net product sales | FY2026 | $600.00M – $620.00M | – | New | Apr 30, 2026 |
| EXPAREL net product sales | FY2026 | $600.00M – $620.00M | – | New | Feb 26, 2026 |
| Non-GAAP R&D expensenon-GAAP | FY2026 | $105.00M – $115.00M | $105.00M – $115.00M | Lowered | Aug 4, 2026 |
| Non-GAAP R&D expensenon-GAAP | FY2026 | $105.00M – $115.00M | – | New | Feb 26, 2026 |
| Non-GAAP SG&A expensenon-GAAP | FY2026 | $310.00M – $330.00M | $320.00M – $340.00M | Raised | Aug 4, 2026 |
| Non-GAAP SG&A expensenon-GAAP | FY2026 | $320.00M – $340.00M | – | Raised | Feb 26, 2026 |
| Research and development expenseGAAP | FY2026 | $115.00M – $128.00M | $116.00M – $128.00M | Lowered | Aug 4, 2026 |
| Research and development expenseGAAP | FY2026 | $116.00M – $128.00M | – | New | Feb 26, 2026 |
| Selling, general and administrative expenseGAAP | FY2026 | $349.00M – $376.00M | $359.00M – $386.00M | Raised | Aug 4, 2026 |
| Selling, general and administrative expenseGAAP | FY2026 | $359.00M – $386.00M | – | Raised | Feb 26, 2026 |
| Stock-based compensation | FY2026 | $54.00M – $59.00M | $54.00M – $62.00M | Lowered | Aug 4, 2026 |
| Stock-based compensation | FY2026 | $54.00M – $62.00M | – | Lowered | Feb 26, 2026 |
Guidance vs results
The last range Pacira BioSciences gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $725.00M – $735.00M | $726.40MΣ4Q | Within range |
Guidance history
Every forecast Pacira BioSciences put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 4, 2026 | Non-GAAP gross margin | FY2026 | 77% – 79% | Reaffirmed |
| Aug 4, 2026 | Gross margin | FY2026 | 76% – 78% | Reaffirmed |
| Aug 4, 2026 | Research and development expense | FY2026 | $115.00M – $128.00M | Lowered |
| Aug 4, 2026 | Selling, general and administrative expense | FY2026 | $349.00M – $376.00M | Raised |
| Aug 4, 2026 | Non-GAAP SG&A expense | FY2026 | $310.00M – $330.00M | Raised |
| Aug 4, 2026 | Non-GAAP R&D expense | FY2026 | $105.00M – $115.00M | Lowered |
| Aug 4, 2026 | Stock-based compensation | FY2026 | $54.00M – $59.00M | Lowered |
| Aug 4, 2026 | Total revenue | FY2026 | $735.00M – $760.00M | Raised |
| Aug 4, 2026 | EXPAREL net product sales | FY2026 | $600.00M – $620.00M | Lowered |
| Apr 30, 2026 | Gross margin | FY2026 | 76% – 78% | New |
| Apr 30, 2026 | Non-GAAP gross margin | FY2026 | 77% – 79% | New |
| Apr 30, 2026 | EXPAREL net product sales | FY2026 | $600.00M – $620.00M | New |
| Apr 30, 2026 | Stock-based compensation | FY2026 | $54.00M – $62.00M | Lowered |
| Apr 30, 2026 | Research and development expense | FY2026 | $116.00M – $128.00M | New |
| Apr 30, 2026 | Selling, general and administrative expense | FY2026 | $359.00M – $386.00M | Raised |
| Apr 30, 2026 | Non-GAAP R&D expense | FY2026 | $105.00M – $115.00M | New |
| Apr 30, 2026 | Non-GAAP SG&A expense | FY2026 | $320.00M – $340.00M | Raised |
| Apr 30, 2026 | Total revenue | FY2026 | $745.00M – $770.00M | New |
| Feb 26, 2026 | Gross margin | FY2026 | 76% – 78% | New |
| Feb 26, 2026 | Non-GAAP gross margin | FY2026 | 77% – 79% | New |
| Feb 26, 2026 | EXPAREL net product sales | FY2026 | $600.00M – $620.00M | New |
| Feb 26, 2026 | Stock-based compensation | FY2026 | $54.00M – $62.00M | Lowered |
| Feb 26, 2026 | Research and development expense | FY2026 | $116.00M – $128.00M | New |
| Feb 26, 2026 | Selling, general and administrative expense | FY2026 | $359.00M – $386.00M | Raised |
| Feb 26, 2026 | Non-GAAP R&D expense | FY2026 | $105.00M – $115.00M | New |
| Feb 26, 2026 | Non-GAAP SG&A expense | FY2026 | $320.00M – $340.00M | Raised |
| Feb 26, 2026 | Total revenue | FY2026 | $745.00M – $770.00M | New |
| Nov 6, 2025 | Gross margin | FY2025 | 78% – 80% | New |
| Nov 6, 2025 | Non-GAAP gross margin | FY2025 | 80% – 82% | New |
| Nov 6, 2025 | Stock-based compensation | FY2025 | $56.00M – $59.00M | New |
| Nov 6, 2025 | Research and development expense | FY2025 | $106.00M – $118.00M | New |
| Nov 6, 2025 | Selling, general and administrative expense | FY2025 | $351.00M – $364.00M | Raised |
| Nov 6, 2025 | Non-GAAP R&D expense | FY2025 | $95.00M – $105.00M | New |
| Nov 6, 2025 | Non-GAAP SG&A expense | FY2025 | $310.00M – $320.00M | Raised |
| Nov 6, 2025 | Total revenue | FY2025 | $725.00M – $735.00M | New |
| Aug 5, 2025 | Gross margin | FY2025 | 76% – 78% | New |
| Aug 5, 2025 | Non-GAAP gross margin | FY2025 | 78% – 80% | Raised |
| Aug 5, 2025 | Stock-based compensation | FY2025 | $56.00M – $61.00M | Reaffirmed |
| Aug 5, 2025 | Research and development expense | FY2025 | $101.00M – $118.00M | New |
| Aug 5, 2025 | Selling, general and administrative expense | FY2025 | $331.00M – $366.00M | Raised |
| Aug 5, 2025 | Non-GAAP R&D expense | FY2025 | $90.00M – $105.00M | Lowered |
| Aug 5, 2025 | Non-GAAP SG&A expense | FY2025 | $290.00M – $320.00M | Raised |
| Aug 5, 2025 | Total revenue | FY2025 | $730.00M – $750.00M | Narrowed |
| May 8, 2025 | Non-GAAP gross margin | FY2025 | 76% – 78% | Reaffirmed |
| May 8, 2025 | Stock-based compensation | FY2025 | $56.00M – $61.00M | Reaffirmed |
| May 8, 2025 | Non-GAAP R&D expense | FY2025 | $90.00M – $105.00M | Lowered |
| May 8, 2025 | Non-GAAP SG&A expense | FY2025 | $290.00M – $320.00M | Raised |
| May 8, 2025 | Total revenue | FY2025 | $725.00M – $765.00M | New |
| Feb 27, 2025 | Non-GAAP gross margin | FY2025 | 76% – 78% | New |
| Feb 27, 2025 | Stock-based compensation | FY2025 | $56.00M – $61.00M | New |
| Feb 27, 2025 | Non-GAAP R&D expense | FY2025 | $90.00M – $105.00M | New |
| Feb 27, 2025 | Non-GAAP SG&A expense | FY2025 | $290.00M – $320.00M | Raised |
| Feb 27, 2025 | Total revenue | FY2025 | $725.00M – $765.00M | New |
| Nov 6, 2024 | Non-GAAP gross margin | FY2024 | 74% – 76% | Reaffirmed |
| Nov 6, 2024 | Stock-based compensation | FY2024 | $50.00M – $55.00M | Reaffirmed |
| Nov 6, 2024 | Non-GAAP R&D expense | FY2024 | $70.00M – $80.00M | Lowered |
| Nov 6, 2024 | Non-GAAP SG&A expense | FY2024 | $245.00M – $265.00M | Raised |
| Nov 6, 2024 | Total revenue | FY2024 | $680.00M – $705.00M | Reaffirmed |
| Jul 30, 2024 | Non-GAAP gross margin | FY2024 | 74% – 76% | Reaffirmed |
| Jul 30, 2024 | Stock-based compensation | FY2024 | $50.00M – $55.00M | Reaffirmed |
| Jul 30, 2024 | Non-GAAP R&D expense | FY2024 | $70.00M – $80.00M | Lowered |
| Jul 30, 2024 | Non-GAAP SG&A expense | FY2024 | $245.00M – $265.00M | Raised |
| Jul 30, 2024 | Total revenue | FY2024 | $680.00M – $705.00M | Reaffirmed |
| May 7, 2024 | Gross margin | FY2024 | 73% – 75% | New |
| May 7, 2024 | Non-GAAP gross margin | FY2024 | 74% – 76% | Reaffirmed |
| May 7, 2024 | Stock-based compensation | FY2024 | $50.00M – $55.00M | New |
| May 7, 2024 | Research and development expense | FY2024 | $78.00M – $90.00M | Raised |
| May 7, 2024 | Selling, general and administrative expense | FY2024 | $280.00M – $310.00M | Raised |
| May 7, 2024 | Non-GAAP R&D expense | FY2024 | $70.00M – $80.00M | Lowered |
| May 7, 2024 | Non-GAAP SG&A expense | FY2024 | $245.00M – $265.00M | Raised |
| May 7, 2024 | Total revenue | FY2024 | $680.00M – $705.00M | New |
| Feb 29, 2024 | Non-GAAP gross margin | FY2024 | 74% – 76% | New |
| Feb 29, 2024 | Stock-based compensation | FY2024 | $50.00M – $55.00M | New |
| Feb 29, 2024 | Non-GAAP R&D expense | FY2024 | $70.00M – $80.00M | New |
| Feb 29, 2024 | Non-GAAP SG&A expense | FY2024 | $245.00M – $265.00M | Raised |
| Feb 29, 2024 | Total revenue | FY2024 | $680.00M – $705.00M | New |
| Nov 2, 2023 | Gross margin | FY2023 | 71% – 72% | Lowered |
| Nov 2, 2023 | Non-GAAP gross margin | FY2023 | 73% – 74% | Reaffirmed |
| Nov 2, 2023 | Stock-based compensation | FY2023 | $46.00M – $49.00M | Reaffirmed |
| Nov 2, 2023 | Research and development expense | FY2023 | $77.00M – $88.00M | Raised |
| Nov 2, 2023 | Selling, general and administrative expense | FY2023 | $252.00M – $264.00M | Raised |
| Nov 2, 2023 | Non-GAAP R&D expense | FY2023 | $70.00M – $80.00M | Lowered |
| Nov 2, 2023 | Non-GAAP SG&A expense | FY2023 | $220.00M – $230.00M | Raised |
| Nov 2, 2023 | EXPAREL net product sales | FY2023 | $535.00M – $540.00M | Raised |
| Nov 2, 2023 | ZILRETTA net product sales | FY2023 | $110.00M – $115.00M | Lowered |
| Nov 2, 2023 | iovera° net product sales | FY2023 | $17.00M – $20.00M | Lowered |
| Aug 2, 2023 | Non-GAAP gross margin | FY2023 | 73% – 74% | Lowered |
| Aug 2, 2023 | Stock-based compensation | FY2023 | $46.00M – $49.00M | New |
| Aug 2, 2023 | Non-GAAP R&D expense | FY2023 | $70.00M – $80.00M | Lowered |
| Aug 2, 2023 | Non-GAAP SG&A expense | FY2023 | $220.00M – $230.00M | Raised |
| Aug 2, 2023 | EXPAREL net product sales | FY2023 | $550.00M – $560.00M | New |
| Aug 2, 2023 | ZILRETTA net product sales | FY2023 | $110.00M – $115.00M | Lowered |
| Aug 2, 2023 | iovera° net product sales | FY2023 | $17.00M – $20.00M | Lowered |
| May 3, 2023 | Gross margin | FY2023 | 74% – 76% | Lowered |
| May 3, 2023 | Non-GAAP Gross margin | FY2023 | 76% – 78% | Reaffirmed |
| May 3, 2023 | Research and development expense | FY2023 | $78.00M – $89.00M | Raised |
| May 3, 2023 | Selling, general and administrative expense | FY2023 | $257.00M – $269.00M | Raised |
| May 3, 2023 | Stock-based compensation | FY2023 | $51.00M – $54.00M | Lowered |
| May 3, 2023 | Non-GAAP R&D expense | FY2023 | $70.00M – $80.00M | Lowered |
| May 3, 2023 | Non-GAAP SG&A expense | FY2023 | $220.00M – $230.00M | Raised |
| May 3, 2023 | EXPAREL net product sales | FY2023 | $570.00M – $580.00M | Raised |
| May 3, 2023 | ZILRETTA net product sales | FY2023 | $115.00M – $125.00M | Lowered |
| May 3, 2023 | iovera° net product sales | FY2023 | $17.00M – $20.00M | Lowered |
| Feb 28, 2023 | Gross margin | FY2023 | 75% – 77% | New |
| Feb 28, 2023 | Non-GAAP Gross margin | FY2023 | 76% – 78% | New |
| Feb 28, 2023 | Research and development expense | FY2023 | $78.00M – $89.00M | New |
| Feb 28, 2023 | Selling, general and administrative expense | FY2023 | $257.00M – $278.00M | Raised |
| Feb 28, 2023 | Stock-based compensation | FY2023 | $51.00M – $54.00M | Lowered |
| Feb 28, 2023 | Non-GAAP R&D expense | FY2023 | $70.00M – $80.00M | New |
| Feb 28, 2023 | Non-GAAP SG&A expense | FY2023 | $220.00M – $230.00M | Raised |
| Feb 28, 2023 | EXPAREL net product sales | FY2023 | $570.00M – $580.00M | New |
| Feb 28, 2023 | ZILRETTA net product sales | FY2023 | $115.00M – $125.00M | Lowered |
| Feb 28, 2023 | iovera° net product sales | FY2023 | $17.00M – $20.00M | Lowered |
| Nov 3, 2022 | Stock-based compensation | FY2022 | $47.00M – $50.00M | Reaffirmed |
| Nov 3, 2022 | Non-GAAP R&D expense | FY2022 | $75.00M – $85.00M | Lowered |
| Nov 3, 2022 | Non-GAAP SG&A expense | FY2022 | $220.00M – $230.00M | Raised |
| Aug 3, 2022 | stock-based compensation | FY2022 | $47.00M – $50.00M | Raised |
| Aug 3, 2022 | Non-GAAP R&D expense | FY2022 | $75.00M – $85.00M | Lowered |
| Aug 3, 2022 | Non-GAAP SG&A expense | FY2022 | $220.00M – $230.00M | Raised |
| May 4, 2022 | Stock-based compensation | FY2022 | $40.00M – $45.00M | Reaffirmed |
| May 4, 2022 | Non-GAAP R&D expense | FY2022 | $75.00M – $85.00M | Lowered |
| May 4, 2022 | Non-GAAP SG&A expense | FY2022 | $220.00M – $230.00M | Raised |
| Feb 24, 2022 | Stock-based compensation | FY2022 | $40.00M – $45.00M | New |
| Feb 24, 2022 | Non-GAAP R&D expense | FY2022 | $75.00M – $85.00M | New |
| Feb 24, 2022 | Non-GAAP SG&A expense | FY2022 | $220.00M – $230.00M | Raised |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Pacira BioSciences filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- News
- Results
- Results
- Update
- Results
- Results
- Results
- Update
- Results
- Update
- Results
See a number that looks wrong?